Hepatotoxic substance(s) removed by high-flux membranes enhances the positive acute phase response

Kidney International, Supplement

Volumn 59, Issue 78, 2001, Pages S308-S314

  Riegel, Werner ^a,b   Ulrich, Christof ^a,b   Sauernheimer, Sigrid ^a,b   Deppisch, Reinhold M ^a,b   Köhler, Hans ^a,b  

^a SAARLAND UNIVERSITY   (Germany)

^b KLINIKUM DARMSTADT   (Germany)

Author keywords

Acute phase proteins; Dialysis; End stage renal disease; Hepatocytes; Liver; Metabolism; Uremic toxin

Indexed keywords

ACUTE PHASE PROTEIN; OROSOMUCOID; TOXIN;

ADULT; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CROSSOVER PROCEDURE; CYTOTOXICITY; DIALYSIS; DIALYSIS MEMBRANE; HEPATOMA CELL; HUMAN; HUMAN CELL; KIDNEY DISEASE; LIVER CELL; LIVER TOXICITY; PRIORITY JOURNAL; UREMIA; ACUTE PHASE RESPONSE; AGED; ARTICLE; ARTIFICIAL KIDNEY; BIOSYNTHESIS; CELL LINE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG EFFECT; ISOLATION AND PURIFICATION; LIVER; METABOLISM; MIDDLE AGED; OSMOLARITY; PH; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; ULTRAFILTRATION;

ACUTE-PHASE REACTION; AGED; CELL LINE; CROSS-OVER STUDIES; CROSS-SECTIONAL STUDIES; HEPATOCYTES; HUMANS; HYDROGEN-ION CONCENTRATION; KIDNEY FAILURE, CHRONIC; KIDNEY, ARTIFICIAL; LIVER; MIDDLE AGED; OROSOMUCOID; OSMOLAR CONCENTRATION; RENAL DIALYSIS; TOXINS, BIOLOGICAL; ULTRAFILTRATION;

EID: 0035126276     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2001.59780308.x     Document Type: Article

References (23)

1. Enhanced generation of interleukins 1 beta and 6 may contribute to cachexia of chronic disease
2. Factors influencing serum albumin in dialysis patients
3. Malnutrition, cardiac disease, and mortality: An integrated point of view
4. Acute-phase inflammatory process contributes to malnutrition, anemia, and possibly other abnormalities in dialysis patients
5. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: A prospective study
6. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis
7. Clinical implications of hemodialysis membrane biocompatibility
8. GIP and DIP: A new view of uremic toxicity
9. Contributing factors to the inhibition of phagocytosis in hemodialyzed patients
10. Physicochemical characterisation of a polypeptide present in uremic serum that inhibits the biological activity of polymorphonuclear cells
11. Hemofiltration in human sepsis: Evidence for elimination of immunomodulatory substances
12. The biochemical and cellular basis of cell proliferation assays that use tetrazolium salts
13. Nutrition and mortality in hemodialysis
14. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities
15. Quantitative tests of liver function
16. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients
17. Serum and urinary alpha-1 acid glycoprotein in chronic renal failure
18. Serum alpha-1 acid glycoprotein in chronic renal failure
19. The acute phase response
20. Interaction among hepatocyte-stimulating factors, interleukin 1 and glucocorticoids for regulation of acute phase plasma proteins in human hepatoma (HepG2) cells
21. Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia
22. Improvement in lipid profiles and triglyceride removal in patients on polyamide membrane hemodialysis
23. High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients